Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
CB-03-01 (Clascoterone)
Also known as: Breezula, Winlevi, CB-03-01, Cortexolone 17α-propionate
Clascoterone is a topical androgen receptor antagonist approved by the FDA in 2020 for acne (Winlevi 1% cream). It is currently in Phase III trials for androgenetic alopecia under the brand name Breezula (7.5% solution). It is the first topical anti-androgen to achieve FDA approval for any dermatological indication and may become the first for hair loss.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 19608-29-8 |
| Molecular Formula | C24H34O5 |
| Class | Other |
| Category | Hair Loss Compounds |
Mechanism of Action
Clascoterone (cortexolone 17-alpha-propionate) competes with DHT and testosterone for binding to the androgen receptor in skin and hair follicle cells. Unlike systemic anti-androgens, it is rapidly metabolized to cortexolone upon systemic absorption, which has minimal hormonal activity. This provides local anti-androgen effect without systemic anti-androgenic side effects such as sexual dysfunction or feminization.
Dosing Research
Acne (approved): Winlevi 1% cream applied twice daily. Hair loss (Phase III trials): Breezula 7.5% solution applied once daily to affected scalp areas. Trial duration for hair loss studies: 12 months. Commercial availability for hair loss pending regulatory approval. The 7.5% hair solution is not yet commercially available in most markets.
Side Effects & Risks
Well-tolerated in clinical trials. Mild application site reactions (erythema, pruritus, dryness). No systemic anti-androgenic effects observed in trials (no sexual dysfunction, no hormonal changes). Minimal systemic absorption. Very favorable safety profile compared to finasteride/dutasteride. Long-term safety data still accumulating from ongoing trials.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.